Novo Nordisk shares edged higher in premarket after it unveiled major restructuring, cutting 9,000 jobs to save 8 billion Danish crowns ($1.26 billion) annually by 2026. Overhaul refocuses on obesity, diabetes drugs but comes with 9 billion crowns in one-off costs, dragging 2025 profit growth forecast down to 4-10% from as high as 27% earlier. Firm faces tough US competition, Wegovy supply issues.